<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hydroxyzine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hydroxyzine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Hydroxyzine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8544" href="/d/html/8544.html" rel="external">see "Hydroxyzine: Drug information"</a> and <a class="drug drug_patient" data-topicid="10748" href="/d/html/10748.html" rel="external">see "Hydroxyzine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F181115"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Vistaril</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867152"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Atarax;</li>
<li>NOVO-Hydroxyzin;</li>
<li>PMS-HydrOXYzine HCl [DSC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1053308"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antianxiety Agent</span>;</li>
<li>
<span class="list-set-name">Antiemetic</span>;</li>
<li>
<span class="list-set-name">Antihistamine</span>;</li>
<li>
<span class="list-set-name">Sedative</span></li></ul></div>
<div class="block dop drugH1Div" id="F181139"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="13892f31-15e7-4ae3-82bd-b19baeac0f6e">Antiemetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Antiemetic:</b>
<b> Note:</b> Expert recommendations for postoperative nausea and vomiting (PONV) management do not suggest hydroxyzine as a therapeutic option; use has typically been replaced by newer agents with an improved safety profile (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32467512']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32467512'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IM: 1.1 mg/kg/dose; maximum dose: 100 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="681d778e-2c1e-46c3-9264-d477867f0a71">Anxiety</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anxiety: </b>
<b>Note:</b> Although FDA approved for use in anxiety, data in pediatric patients are sparse; expert recommendations for pediatric patients do not consider hydroxyzine a therapeutic option for the management of anxiety disorders (eg, generalized anxiety disorder, separation anxiety, specific phobias, panic disorder, post-traumatic stress disorder); use has generally been replaced by newer, more effective agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32439401','lexi-content-ref-29099547','lexi-content-ref-26763675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32439401','lexi-content-ref-29099547','lexi-content-ref-26763675'])">Ref</a></span>). In adults, a lower daily dosing regimen of 37.5 to 75 mg/day in divided doses is recommended by experts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18949648','lexi-content-ref-22540422']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18949648','lexi-content-ref-22540422'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;6 years: Oral: 12.5 mg 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DeMaso.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DeMaso.1','lexi-content-ref-Manu.1'])">Ref</a></span>); although FDA approved, expert guidelines do not recommend pharmacotherapy in patients &lt;6 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32439401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32439401'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Oral: 12.5 to 25 mg 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DeMaso.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DeMaso.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7f9b96f3-a544-495e-a5a2-9adf0207d8de">Pruritus; associated with allergic conditions or chronic urticaria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pruritus; associated with allergic conditions or chronic urticaria:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Age-directed dosing:</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;6 years: Oral: 12.5 mg 3 to 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelson.1996','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelson.1996','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥6 years and Adolescents: Oral: 12.5 to 25 mg 3 to 4 times daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelson.1996','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelson.1996','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Based on pharmacokinetic studies, dosing once daily (at bedtime) or twice daily may be adequate due to the long half-life (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6141198']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6141198'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-directed dosing:</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight ≤40 kg: Oral: 2 mg/kg/<b>day</b> divided every 6 to 8 hours as needed; maximum dose: 25 mg/dose. <b>Note:</b> Based on pharmacokinetic studies, dosing once daily (at bedtime) or twice daily may be adequate due to the long half-life (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Nelson.1996','lexi-content-ref-7909915','lexi-content-ref-6361228','lexi-content-ref-6141198']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Nelson.1996','lexi-content-ref-7909915','lexi-content-ref-6361228','lexi-content-ref-6141198'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Patient weight &gt;40 kg: Oral: 25 to 50 mg once daily at bedtime or twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7909915','lexi-content-ref-6141198']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7909915','lexi-content-ref-6141198'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="01341f97-e00d-4b92-a388-e4c92bd8323d">Pruritus; associated with opioid use</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pruritus; associated with opioid use:</b> Limited data available: Children and Adolescents: IM, Oral: 0.5 mg/kg/dose every 6 hours as needed; usual maximum dose: 50 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2216644','lexi-content-ref-Zeltzer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2216644','lexi-content-ref-Zeltzer.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a49d26b5-cd4b-4e1e-af2e-5c167801c908">Sedation; pre-/postoperative, adjunctive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation; pre-/postoperative, adjunctive therapy: Note:</b> Although FDA approved, pre-/postoperative hydroxyzine use has largely been replaced by other agents.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Children and Adolescents: Oral: 0.6 mg/kg/dose; maximum dose: 100 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Infants, Children, and Adolescents: IM: 1.1 mg/kg/dose; maximum dose: 100 mg/dose.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="614be1b8-932d-4f1a-98fe-5e7ddc722ea0">Sedation; procedural, adjunctive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sedation; procedural, adjunctive therapy (eg, dental, echocardiography): </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 2 to 12 years: Oral: 1 mg/kg/dose as a single dose 30 to 45 minutes prior to procedure in combination with other sedatives (eg, midazolam, chloral hydrate) has been used in children prior to dental procedures or echocardiograms; maximum dose: 100 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16173222','lexi-content-ref-30355430','lexi-content-ref-20047024','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16173222','lexi-content-ref-30355430','lexi-content-ref-20047024','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51113382"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> There are no data on hydroxyzine pharmacokinetics in kidney impairment; however, based on adult data, the active metabolite, cetirizine, is cleared by the kidney and may accumulate in patients with kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2892446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2892446'])">Ref</a></span>). Additionally, hydroxyzine was associated with QTc prolongation in a cohort of adult patients with chronic kidney insufficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28793999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28793999'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral, IM:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Mild impairment:</i> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Canada.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Canada.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Moderate to severe impairment:</i> Administer ~50% of usual dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Canada.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Canada.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent:</b> Hydroxyzine is unlikely to be significantly dialyzed (due to large V<sub>d</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>)) and its metabolite (cetirizine) is &lt;10% dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1970299','lexi-content-ref-11528239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1970299','lexi-content-ref-11528239'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51159567"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific recommendations; based on experience in adults with primary biliary cirrhosis, increasing length of dosing interval is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2572611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2572611'])">Ref</a></span>).</p></div>
<div class="block doa drugH1Div" id="F181118"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8544" href="/d/html/8544.html" rel="external">see "Hydroxyzine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1d6a3c0c-3b83-46a9-b8d0-129c6a0a77a2">Anxiety, monotherapy or adjunctive therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anxiety, monotherapy or adjunctive therapy (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be useful for insomnia associated with anxiety or for short-term immediate control of symptoms until maintenance therapy is effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.2021','lexi-content-ref-25081580']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.2021','lexi-content-ref-25081580'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Usual dosage range: 25 to 50 mg up to 4 times daily, as needed; may increase based on response and tolerability up to 400 mg/day; maximum single dose: 100 mg. For insomnia associated with anxiety, administer at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.2021','lexi-content-ref-12444816','lexi-content-ref-Roy-Byrne.2020','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.2021','lexi-content-ref-12444816','lexi-content-ref-Roy-Byrne.2020','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4db80c08-f81a-40bd-b2c3-2273779fb2c1">Peripartum management, adjunct to opioids</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peripartum management, adjunct to opioids:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used to potentiate opioid analgesia and decrease side effects (eg, nausea and vomiting).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> 25 to 50 mg as a single dose; may repeat after 4 hours if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-5342863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-5342863'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="89d6bc99-18f1-46c6-acd4-c58717d97834">Pruritus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pruritus:</b>
<b>Oral:</b> 10 to 25 mg 3 to 4 times daily as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Goddard.2020','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Goddard.2020','lexi-content-ref-Manu.1'])">Ref</a></span>). Some experts may use single doses up to 50 mg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fazio.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fazio.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f65880a4-134b-4d60-99af-28a6f3dd6eaa">Urticaria, new onset and chronic spontaneous</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Urticaria, new onset and chronic spontaneous (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Second-generation H<sub>1</sub>-antihistamines are preferred due to less sedating and anticholinergic effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24766875','lexi-content-ref-34536239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24766875','lexi-content-ref-34536239'])">Ref</a></span>). May consider use in combination with a second-generation H<sub>1</sub>-antihistamine in patients in whom bedtime sedating effects may be beneficial, <b>or</b> as initial parenteral therapy in patients with new-onset urticaria in whom more rapid onset of action is desired; avoid use in patients with high-risk occupations (eg, pilots, bus drivers) or who may be more prone to anticholinergic effects (eg, older adults) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24766875','lexi-content-ref-32707227','lexi-content-ref-Asero.2020','lexi-content-ref-Khan.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24766875','lexi-content-ref-32707227','lexi-content-ref-Asero.2020','lexi-content-ref-Khan.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 10 to 25 mg at bedtime. May increase in 10 to 25 mg increments at weekly intervals if needed based on response and tolerability; daily dose may be administered at bedtime or in 3 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24766875','lexi-content-ref-Khan.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24766875','lexi-content-ref-Khan.2020'])">Ref</a></span>). Some experts administer daily doses &gt;100 mg in divided doses; do not exceed 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Khan.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Khan.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM (for new onset urticaria only): </b>25 to 50 mg 3 to 4 times per day as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24766875','lexi-content-ref-Asero.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24766875','lexi-content-ref-Asero.2020'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990812"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>There are no data on hydroxyzine pharmacokinetics in kidney impairment; however, the active metabolite, cetirizine, is cleared by the kidney and may accumulate in patients with kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2892446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2892446'])">Ref</a></span>). Additionally, hydroxyzine was associated with QTc prolongation in a cohort of patients with chronic kidney insufficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28793999']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28793999'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IM:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥50 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Canada.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Canada.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to &lt;50 mL/minute: Administer ~50% of usual dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Canada.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Canada.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: Administer ~25% to 50% of usual dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Canada.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Canada.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Hydroxyzine is unlikely to be significantly dialyzed (large V<sub>d</sub> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>)) and its metabolite (cetirizine) is &lt;10% dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1970299','lexi-content-ref-11528239']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1970299','lexi-content-ref-11528239'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IM:</b> Administer 25 to 50% of usual dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzed (large V<sub>d</sub>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, IM:</b> Administer 25 to 50% of usual dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b>
<b>Oral, IM:</b> Administer 50% of usual dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b>
<b>Oral, IM:</b> Administer 50% of usual dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988017"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. In patients with primary biliary cirrhosis, change dosing interval to every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2572611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2572611'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F55724872"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute generalized exanthematous pustulosis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute generalized exanthematous pustulosis </b>(AGEP) has rarely been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21965865','lexi-content-ref-25219740','lexi-content-ref-17927792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21965865','lexi-content-ref-25219740','lexi-content-ref-17927792'])">Ref</a></span>). Resolution generally occurs 2 weeks after drug discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>); although, with hydroxyzine, may occur within 3 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21965865']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21965865'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non–dose-related; immunologic. AGEP is considered a T-cell mediated reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26354880']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26354880'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed: usually within 24 hours after drug initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25219740','lexi-content-ref-17927792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25219740','lexi-content-ref-17927792'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-sensitivity: Not established; conflicting evidence regarding cross-reactivity between hydroxyzine, cetirizine, and levocetirizine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31782151','lexi-content-ref-17927792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31782151','lexi-content-ref-17927792'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">CNS depression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Drowsiness</b> and dizziness may occur, especially after initial doses. These effects may persist the next morning after bedtime dosing causing daytime drowsiness (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728','lexi-content-ref-24472058']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728','lexi-content-ref-24472058'])">Ref</a></span>). Drowsiness is usually transient and subsides after a few consecutive days of therapy or after dose reduction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30949959']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30949959'])">Ref</a></span>). <b>Cognitive dysfunction </b>has been reported after morning and evening dosing, which may impair the ability to drive or operate machinery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728','lexi-content-ref-21508863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728','lexi-content-ref-21508863'])">Ref</a></span>). At recommended doses, clinically significant respiratory depression has not been observed.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>
<i>: </i>Dose related; related to the pharmacologic action (ie, competitive binding to histamine-<sub>1</sub> receptors in the CNS) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; occurs within the first few days of therapy initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21508863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21508863'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose (especially initiation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other CNS depressant medications</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of alcohol (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24395298']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24395298'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20146728']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20146728'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">QT prolongation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hydroxyzine is associated with a conditional risk of<b> prolonged QT interval on ECG</b>, defined as a QTc &gt;500 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31654357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31654357'])">Ref</a></span>). Hydroxyzine-related QT prolongation and <b>torsades de pointes</b> (TdP) have been described in case reports (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33141610','lexi-content-ref-28480041','lexi-content-ref-25622983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33141610','lexi-content-ref-28480041','lexi-content-ref-25622983'])">Ref</a></span>). QTc values return to normal within days to weeks after drug discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19057127','lexi-content-ref-25622983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19057127','lexi-content-ref-25622983'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Human ether-à-go-go (hERG) channel inhibition leading to prolongation of the cardiac action potential (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25622983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25622983'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; typically occurs within 5 days after initial dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19057127','lexi-content-ref-28480041','lexi-content-ref-25622983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19057127','lexi-content-ref-28480041','lexi-content-ref-25622983'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Drug-induced QTc prolongation/TdP (in general):</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Age &gt;65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Structural heart disease (eg, history of myocardial infarction or heart failure with reduced ejection fraction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Martinez.2018','lexi-content-ref-14999113','lexi-content-ref-28480041','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Martinez.2018','lexi-content-ref-14999113','lexi-content-ref-28480041','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Genetic defects of cardiac ion channels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• History of drug-induced TdP (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Congenital long QT syndrome (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Baseline QTc interval prolongation (eg, &gt;500 msec) or lengthening of the QTc by ≥60 msec (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Electrolyte disturbances (eg, hypocalcemia, hypokalemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Martinez.2018','lexi-content-ref-14999113','lexi-content-ref-28480041','lexi-content-ref-32929996','lexi-content-ref-25622983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Martinez.2018','lexi-content-ref-14999113','lexi-content-ref-28480041','lexi-content-ref-32929996','lexi-content-ref-25622983'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Bradycardia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Martinez.2018','lexi-content-ref-14999113','lexi-content-ref-28480041','lexi-content-ref-32929996','lexi-content-ref-25622983']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Martinez.2018','lexi-content-ref-14999113','lexi-content-ref-28480041','lexi-content-ref-32929996','lexi-content-ref-25622983'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hepatic impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14999113','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14999113','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Diuretic use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Sepsis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23716032']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23716032'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concurrent administration of multiple medications (≥2) that prolong the QT interval or medications with drug interactions that increase serum concentrations of QT-prolonging medications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27440957','lexi-content-ref-Martinez.2018','lexi-content-ref-14999113','lexi-content-ref-28480041','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27440957','lexi-content-ref-Martinez.2018','lexi-content-ref-14999113','lexi-content-ref-28480041','lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Drug-specific:</p>
<p style="text-indent:-2em;margin-left:8em;">• hERG gene mutation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19057127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19057127'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F181082"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (transient)</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Respiratory depression (high doses)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Prolonged QT interval on ECG (rare: &lt;1%) (Schlit 2017; Vigne 2015), torsades de pointes (rare: &lt;1%) (Ali 2021; Schlit 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (rare: &lt;1%) (O’Toole 2014), pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Fixed drug eruption (Bhari 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cognitive dysfunction (Church 2010; Conen 2011), hallucination, headache, involuntary body movements, seizure (high doses)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Tremor (high doses)</p></div>
<div class="block coi drugH1Div" id="F181097"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to hydroxyzine or any component of the formulation; early pregnancy; prolonged QT interval.</p>
<p style="text-indent:-2em;margin-left:2em;">Additional contraindications:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Hypersensitivity to cetirizine or levocetirizine.</p>
<p style="text-indent:-2em;margin-left:4em;">Injection: SUBQ, intra-arterial, or IV administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Oral: Hypersensitivity to other piperazine derivatives, aminophylline or ethylenediamine; history of torsade de pointes, including congenital long QT syndromes; history of cardiac arrhythmias; significant electrolyte imbalance (eg, hypokalemia, hypomagnesemia); significant bradycardia; family history of sudden cardiac death; concomitant use with other QT/QTc-prolonging drugs or with CYP3A4/5 inhibitors; asthmatics who have previously experienced a serious anti-histamine induced adverse bronchopulmonary effect; porphyria; patients of childbearing potential.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F181079"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation/torsades de pointes: Oral hydroxyzine is contraindicated in patients with a prolonged QT interval.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with narrow-angle glaucoma; condition may be exacerbated by cholinergic blockade. Screening is recommended.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Use with caution in patients with asthma or chronic obstructive pulmonary disease (COPD).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">Older adult: May cause over sedation in older adults; avoid use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol and/or sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol and/or benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate administration: Parenteral: For IM use only. Severe injection-site reactions have been reported with IM administration (eg, extensive tissue damage, necrosis, gangrene) requiring surgical intervention (including debridement, skin grafting, and amputation). SUBQ, IV, and intra-arterial routes of administration are contraindicated. Intravascular hemolysis, thrombosis, and digital gangrene have been reported with IV or intra-arterial administration (Baumgartner 1979); SUBQ administration may result in significant tissue damage. If <b>inadvertent</b> IV administration results in extravasation, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p>
<p style="text-indent:-2em;margin-left:4em;">• Long-term use: The effectiveness of hydroxyzine for long-term use (&gt;4 months) has not been assessed; periodically reassess use.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878490"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Neonatal withdrawal symptoms, including seizures, have been reported following long-term maternal use or the use of large doses near term (Serreau 2005).</p></div>
<div class="block foc drugH1Div" id="F181090"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as pamoate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vistaril: 25 mg, 50 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/mL (1 mL); 50 mg/mL (1 mL, 2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Syrup, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/5 mL (25 mL, 118 mL, 473 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 25 mg, 50 mg</p></div>
<div class="block geq drugH1Div" id="F181075"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F181100"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (hydrOXYzine Pamoate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.21 - $0.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.22 - $0.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1.19</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Vistaril Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (hydrOXYzine HCl Intramuscular)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/mL (per mL): $30.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $33.76</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Syrup</b> (hydrOXYzine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/5 mL (per mL): $0.16 - $1.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (hydrOXYzine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.11 - $5.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.12 - $5.64</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.17 - $5.94</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867153"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 25 mg, 50 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intramuscular, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg/mL (1 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Syrup, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Atarax: 10 mg/5 mL (473 mL) [contains alcohol, usp, menthol, sodium benzoate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg/5 mL ([DSC])</p></div>
<div class="block admp drugH1Div" id="F52613007"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered without regard to food.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: For IM use only. SUBQ, intra-arterial, and IV administration are contraindicated and <b>not</b> recommended under any circumstances; intravascular hemolysis, thrombosis, and digital gangrene can occur; extravasation can result in sterile abscess and marked tissue induration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-525641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-525641'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Administer IM deep in large muscle. For IM administration in children, injections should be made into the midlateral muscles of the thigh. In infants and children, the upper outer quadrant of the gluteal region should be used only when necessary (eg, burn patients) to minimize potential damage to the sciatic nerve. In adults, the upper outer quadrant of the buttock is considered the preferred injection site. In older children and adolescents, the deltoid region should only be used if well developed and with caution to avoid radial nerve injury. Injections should not be made in the lower or mid-third of the upper arm. Aspirate before injection to avoid inadvertent injection into a blood vessel.</p></div>
<div class="block adm drugH1Div" id="F181094"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> For IM use only. Aspirate before injection to avoid inadvertent injection into a blood vessel. Do <b>NOT</b> administer IV, SUBQ, or intra-arterially (contraindicated). Administer IM deep in large muscle. The preferred site is the upper outer quadrant of the buttock or midlateral thigh. The upper outer quadrant of the gluteal region should be used only when necessary to minimize potential damage to the sciatic nerve. The deltoid region should be only used with caution to avoid radial nerve injury. Injections should not be made in the lower or mid-third of the upper arm.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer without regard to food.</p></div>
<div class="block sts drugH1Div" id="F181110"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules: Store &lt;30°C (86°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Syrup: Store at 15°C to 30°C (59°F to 86°F); protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Store at 20°C to 25°C (68°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53567245"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Treatment of anxiety and pruritus; pre- and postoperative sedation (All indications: FDA approved in pediatric patients [age not specified] and adults).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Although FDA approved for use in anxiety, data in pediatric patients is sparse; expert recommendations for pediatric patients do not consider hydroxyzine a therapeutic option for the management of anxiety disorders (eg, generalized anxiety disorder, separation anxiety, specific phobias, panic disorder, post-traumatic stress disorder); use has generally been replaced by newer, more effective agents (AACAP [Connolly 2007]; Bushnell 2018; Gale 2016).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Perioperative adjunctive sedation and nausea and vomiting (FDA approved in infants, children, adolescents, and adults); treatment of anxiety and pre-/postpartum adjunctive for nausea/vomiting control, anxiety, and opioid dose reduction (FDA approved in adults). <b>Note:</b> Expert recommendations for postoperative nausea and vomiting (PONV) management do not suggest hydroxyzine as a therapeutic option; use has typically been replaced by newer agents with an improved safety profile (SAA [Gan 2014]).</p></div>
<div class="block mst drugH1Div" id="F181169"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">HydrOXYzine may be confused with hydrALAZINE, hydroCHLOROthiazide, HYDROmorphone, hydroxyurea</p>
<p style="text-indent:-2em;margin-left:4em;">Atarax may be confused with Ativan</p>
<p style="text-indent:-2em;margin-left:4em;">Vistaril may be confused with Restoril, Versed, Zestril</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (when used in early pregnancy) among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Hydroxyzine, a first-generation antihistamine, is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its potent anticholinergic properties resulting in increased risk of confusion, dry mouth, constipation, and other anticholinergic effects or toxicity; use should also be avoided due to reduced clearance with advanced age and tolerance associated with use as a hypnotic. Exposure to concurrent anticholinergic drugs also increases risk of falls, delirium, and dementia; consider total anticholinergic burden when conducting medication reviews (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Vistaril [US and Turkey] may be confused with Vastarel brand name for trimetazidine [multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F181155"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F181084"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amezinium: Antihistamines may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine. Betahistine may diminish the therapeutic effect of Antihistamines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Anticholinergic Agents may enhance the constipating effect of CloZAPine.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for signs and symptoms of gastrointestinal hypomotility and consider prophylactic laxative treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: HydrOXYzine may enhance the CNS depressant effect of CNS Depressants.  Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: Antihistamines may diminish the therapeutic effect of Pitolisant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): HydrOXYzine may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F181101"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Hydroxyzine crosses the placenta (Prenner 1977; Serreau 2005).</p>
<p style="text-indent:0em;margin-top:2em;">Based on data from animal reproduction studies, the use of hydroxyzine in early pregnancy is contraindicated. Outcome data following maternal use of hydroxyzine in humans during pregnancy are available (Etwel 2017; Hansen 2020; Heinonen 1977; Kocatürk 2022). Possible withdrawal symptoms have been observed in neonates following chronic maternal use of hydroxyzine during pregnancy (Prenner 1977; Serreau 2005).</p>
<p style="text-indent:0em;margin-top:2em;">Hydroxyzine is approved for pre- and postpartum adjunctive therapy to control emesis, reduce opioid dosage, and treat anxiety. However, agents other than hydroxyzine are recommended for the treatment of nausea and vomiting of pregnancy (ACOG 189 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Algorithms are available for the treatment of urticaria. First-generation oral antihistamines are generally not recommended for use in pregnant patients due to side effects (EAACI [Zuberbier 2022]).</p></div>
<div class="block mopp drugH1Div" id="F53567241"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Mental status, blood pressure, rash (including worsening of preexisting skin reactions).</p></div>
<div class="block pha drugH1Div" id="F181078"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Competes with histamine for H<sub>1</sub>-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract (Simons 1994). Possesses skeletal muscle relaxing, bronchodilator, antihistamine, antiemetic, and analgesic properties. Activity at muscarinic, serotonergic (5HT2), and dopaminergic receptors in the hippocampus, cerebral cortices, and whole brain may produce anxiolytic effects (Guaiana 2010; Sawantdesai 2016).</p></div>
<div class="block phk drugH1Div" id="F181096"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral: 15 to 30 minutes; IM: Rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Decreased histamine-induced wheal and flare areas: 2 to ≥36 hours; Suppression of pruritus: 1 to 12 hours (Simons 1984a).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapid.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Children and Adolescents 1 to 14 years: 18.5 ± 8.6 L/kg (Simons 1984b); Adults: V<sub>d</sub>: 16 ± 3 L/kg (Simons 1984a); Elderly: ~23 L/kg (Simons 1989b); Hepatic dysfunction: ~23 L/kg (Simons 1989a).</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic to multiple metabolites, including cetirizine (active) (Simons 1989a).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 1 to 14 years (mean age: 6.1 ± 4.6 years): 7.1 ± 2.3 hours; <b>Note: </b>Half-life increased with increasing age and was 4 hours in patients 1 year of age and 11 hours in a 14-year-old patient (Simons 1984b).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~20 hours (Simons 1984a); Elderly: ~29 hours (Simons 1989b); Hepatic dysfunction: ~37 hours (Simons 1989a).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Oral administration: Serum: ~2 hours; Peak suppression of antihistamine-induced wheal and flare: 4 to 12 hours (Simons 1984a).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine; active metabolite (cetirizine) is renally eliminated (Simons 1994).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F181102"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ataraxone | Hidroxina | Hyderax | Panaler</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Artica | Atarax | Roxyzin | Xyril</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Neurolax</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de hidroxizina | Dicloridrato de hidroxizina | Droxy | Hidroxine | Hixizine | Prurizin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dalun | Fasarax | Fedox | Nexit</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Hydroxyzine</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Calmofilase | Cedar | Clemaskov | Dormirex | Drowsy | Droxia | Hiderax | Hiderax s | Hidrolan | Hidroxfar | Hidroxicina | Hidroxizina | Histaxina | Indolgin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Ah3 | Atarax | Atarax pb pharma | Elroquil n | Hydroxyzin bluefish</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Droxicin | Hidroxicina | Hyderax | Kalm | Pazz | Seda</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Fasarax | Hidroxicina | Hidroxina</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Hydroxyzin bluefish | Hydroxyzinum vp</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Hidroxicina qualigen | Hidroxizina Bluefish</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Hydroxyzine orifarm | Hydroxyzine sandoz</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Hydroxyzine arrow | Hydroxyzine biogaran | Hydroxyzine Bluefish | Hydroxyzine Cristers | Hydroxyzine EG | Hydroxyzine mylan | Hydroxyzine renaudin | Hydroxyzine sandoz | Hydroxyzine Teva | Hydroxyzine zentiva</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Equipose | Hydroxyzine | Ucerax</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Antipsichos | Atarax | Iremofar</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Allerax | Apo-hydroxyzine | Atarax | Hydroxyzine | Polizine | Qualidrozine | Rozine | Vatarax</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Bestalin | Iterax</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Ucerax</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Otarex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">A rex | Amwin's hysure | Anxidol | Atahist | Atarax | Atazis | Atragence | Atzine | Averzine | Axaria | Braket | D rax | Galadaz | H rax | Hicope | Hydil | Hydrax | Hydroze | Hymax | Hynosure | Hyrax | Hyzine | Ktrax | Oltrex | Pru | Prufree | Prugo | Prunil | Prutrax | Prutrax sr | Prutrip | Psytrax | Urtigo | Urtivel | Urtizen | Vistarax | Zoryz | Zylax</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Newrax</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Alamon | Atarax | Atarax-p | Bobsule | Disron | Disron p | Hatanaziin merck hoei | Hatanazin | Primedoron | Vison | Warazix all | Warazix taiyo</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Adipam | Centilax | Dewbrium | Dudrizine | Hanopam | Hanwha hydroxyzine hydrochloride | Hydroxyzine | Leuzan | Phymorax | Sydraxin | Ucerax | Vistaril</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Hydroxizine | Hydroxyzinum | Neurolax</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Neurolax</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Taraxet</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Akiskam | Apodrox | Atarax | Execut | Hidroxizina | Torefega | Xylam</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo-hydroxyzine | Atarax</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Hydroxyzine-2 Hcl</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Hydroxyzine Bluefish | Hydroxyzine orifarm | Hydroxyzine orion</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Serecid</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Droxiem | Iterax | Sedazine</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Roxyzin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Droxiem | Hydroxyzine orion | Hydroxyzinum | Hydroxyzinum adamed | Hydroxyzinum alvogen | Hydroxyzinum Espefa | Hydroxyzinum hasco | Hydroxyzinum polfarmex | Hydroxyzinum PPH | Hydroxyzinum vp | Hydroxyzinum zentiva</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Hydroxyzine | Hydroxyzine HCL | Hydroxyzine Pam | Hydroxyzine pamoate | Vistaril</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Fenartix | Hidroxizina | Hidroxizina Bluefish | Hidroxizina generis</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Hidroxina | Prurid</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Hydroxyzine | Hydroxyzine canon | Hydroxyzine nativ | Hydroxyzine vertex</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo-hydroxyzine | Atarax</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Atyxine | Hydroxizin alternova | Hydroxyzine | Hydroxyzine Bluefish | Hydroxyzine orifarm | Hydroxyzine orion | Vistaril</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Aa pharma hydroxyzine | Apo-hydroxyzine | Atarax | Hizin | Navicalm | Phymorax</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Atarax</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Abacus | Abelax | Abelex | Actadon | Aldrarax | Alerax-fc | Allerax | Alzin | Ammipam Ms | Andrarax | Antipru | Antizine | Antorex | Ata | Atalog | Atamed | Atano | Atarax | Ataril | Ataril F | Atarine | Atryl | Bemax | Buxie | Calmarax | Cerax | Colluzine | Darax | Dicarax | Dormirax | Drazine | Droxim | Drozine | Dyzine | Goose Hyzine | Hadarax | Hadoxine | Histan | Hiszine | Hizin | Honsa | Hycin | Hydan | Hydrarax | Hydrox | Hydroxin | Hydroxyzine | Hyrax | Hyzine | Katrax | Malax | Masarax | Morax | P.D.Rax | Pipzine | Polizine | Postarax | Prurancit | R rax | Raxta | Raxzin | Sinny | Taraxin | Trandrozine | Unamine | Unirax | Vestarax | Xara | Xaxa | Xyzine | Zeniz</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Iremofar</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Vistaril</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Arax | Atarax | Disron | Nirax | Vistaril</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Atarax | Hydroxyzine zn</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ataraxone | Hidroxin | Hidroxina</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Philhydarax</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Aterax | Micro-hydroxyzine | Pharma Q Hydroxyzine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29266076">
<a name="29266076"></a>ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin no. 189: nausea and vomiting of pregnancy. <i>Obstet Gynecol</i>. 2018;131(1):e15-e30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/29266076/pubmed" id="29266076" target="_blank">29266076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27440957">
<a name="27440957"></a>Acosta-Materán C, Díaz-Oliva E, Fernández-Rodríguez D, Hernández-Afonso J. QT interval prolongation and torsade de pointes: Synergistic effect of flecainide and H1 receptor antagonists. <i>J Pharmacol Pharmacother</i>. 2016 Apr-Jun;7(2):102-5. doi:10.4103/0976-500X.184776<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/27440957/pubmed" id="27440957" target="_blank">27440957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33141610">
<a name="33141610"></a>Ali Z, Ismail M, Khan F, Sajid H. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system. <i>Expert Opin Drug Saf</i>. 2021;20(1):101-107. doi:10.1080/14740338.2021.1846717<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/33141610/pubmed" id="33141610" target="_blank">33141610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Asero.2020">
<a name="Asero.2020"></a>Asero R. New-onset urticaria. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Atarax.2016.05">
<a name="Atarax.2016.05"></a>Atarax (hydroxyzine) oral solution, USP [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1970299">
<a name="1970299"></a>Awni WM, Yeh J, Halstenson CE, Opsahl JA, Chung M, Matzke GR. Effect of haemodialysis on the pharmacokinetics of cetirizine. <i>Eur J Clin Pharmacol</i>. 1990;38(1):67-69. doi:10.1007/BF00314806<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/1970299/pubmed" id="1970299" target="_blank">1970299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22540422">
<a name="22540422"></a>Bandelow B, Sher L, Bunevicius R, et al. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. <i>Int J Psychiat Clin</i>. 2012;16:77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/22540422/pubmed" id="22540422" target="_blank">22540422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18949648">
<a name="18949648"></a>Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, First Revision. <i>World J Biol Psychiatry</i>. 2008;9(4):248-312.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/18949648/pubmed" id="18949648" target="_blank">18949648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-525641">
<a name="525641"></a>Baumgartner T. Administration of Hydroxyzine Injection. <i>Am J Hosp Pharm.</i> 1979;36(12):1660.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/525641/pubmed" id="525641" target="_blank">525641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2216644">
<a name="2216644"></a>Berde C, Ablin A, Glazer J, et al. American Academy of Pediatrics Report of the Subcommittee on Disease-Related Pain in Childhood Cancer. <i>Pediatrics.</i> 1990;86(5 Pt 2):818-825.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/2216644/pubmed" id="2216644" target="_blank">2216644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24766875">
<a name="24766875"></a>Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. <i>J Allergy Clin Immunol</i>. 2014;133(5):1270-1277. doi:10.1016/j.jaci.2014.02.036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/24766875/pubmed" id="24766875" target="_blank">24766875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27612321">
<a name="27612321"></a>Bhari N, Mahajan R, Singh S, Sharma VK. Fixed drug eruption due to three antihistamines of a same chemical family: Cetirizine, levocetirizine, and hydroxyzine. <i>Dermatol Ther</i>. 2017;30(2). doi:10.1111/dth.12412<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/27612321/pubmed" id="27612321" target="_blank">27612321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29099547">
<a name="29099547"></a>Bushnell GA, Compton SN, Dusetzina SB, et al. Treating pediatric anxiety: initial use of SSRIs and other antianxiety prescription medications. <i>J Clin Psychiatry</i>. 2018;79(1). pii: 16m11415.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/29099547/pubmed" id="29099547" target="_blank">29099547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528912">
<a name="24528912"></a>Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: part II. Lactation. <i>J Am Acad Dermatol</i>. 2014;70(3):417. doi:10.1016/j.jaad.2013.09.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/24528912/pubmed" id="24528912" target="_blank">24528912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20146728">
<a name="20146728"></a>Church MK, Maurer M, Simons FE, et al; Global Allergy and Asthma European Network. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. <i>Allergy</i>. 2010;65(4):459-466. doi:10.1111/j.1398-9995.2009.02325.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/20146728/pubmed" id="20146728" target="_blank">20146728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16173222">
<a name="16173222"></a>Chowdhury J, Vargas KG. Comparison of chloral hydrate, meperidine, and hydroxyzine to midazolam regimens for oral sedation of pediatric dental patients. <i>Pediatr Dent</i>. 2005;27(3):191-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/16173222/pubmed" id="16173222" target="_blank">16173222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21508863">
<a name="21508863"></a>Conen S, Theunissen EL, Vermeeren A, Ramaekers JG. Short-term effects of morning versus evening dose of hydroxyzine 50 mg on cognition in healthy volunteers. <i>J Clin Psychopharmacol</i>. 2011;31(3):294-301. doi:10.1097/JCP.0b013e318218943c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/21508863/pubmed" id="21508863" target="_blank">21508863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17242630">
<a name="17242630"></a>Connolly SD, Bernstein GA; Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(2):267-283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/17242630/pubmed" id="17242630" target="_blank">17242630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craske.2021">
<a name="Craske.2021"></a>Craske M, Bystritsky A. Generalized anxiety disorder in adults: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 15, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17333576">
<a name="17333576"></a>Dasgupta A, Wells A, Datta P. False-positive serum tricyclic antidepressant concentrations using fluorescence polarization immunoassay due to the presence of hydroxyzine and cetirizine. <i>Ther Drug Monit.</i> 2007;29(1):134-139.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/17333576/pubmed" id="17333576" target="_blank">17333576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DeMaso.1">
<a name="DeMaso.1"></a>DeMaso DR, Walter HJ. Psychopharmacology. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 33.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32707227">
<a name="32707227"></a>Dykewicz MS, Wallace DV, Amrol DJ, et al; Joint Task Force on Practice Parameters; Workgroup Contributors. Rhinitis 2020: a practice parameter update. <i>J Allergy Clin Immunol</i>. 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/32707227/pubmed" id="32707227" target="_blank">32707227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27878468">
<a name="27878468"></a>Etwel F, Faught LH, Rieder MJ, Koren G. The risk of adverse pregnancy outcome after first trimester exposure to H1 antihistamines: a systematic review and meta-analysis. <i>Drug Saf</i>. 2017;40(2):121-132. doi:10.1007/s40264-016-0479-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/27878468/pubmed" id="27878468" target="_blank">27878468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fazio.1">
<a name="Fazio.1"></a>Fazio SB, Yosipovitch G. Pruritus: therapies for generalized pruritus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26763675">
<a name="26763675"></a>Gale CK, Millichamp J. Generalised anxiety disorder in children and adolescents. <i>BMJ Clin Evid</i>. 2016;2016. pii: 1002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/26763675/pubmed" id="26763675" target="_blank">26763675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32467512">
<a name="32467512"></a>Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. <i>Anesth Analg</i>. 2020;131(2):411-448. doi:10.1213/ANE.0000000000004833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/32467512/pubmed" id="32467512" target="_blank">32467512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24356162">
<a name="24356162"></a>Gan TJ, Diemunsch P, Habib AS, et al; Society for Ambulatory Anesthesia (SAA). Consensus guidelines for the management of postoperative nausea and vomiting [published corrections appear in <i>Anesth Analg</i>. 2015;120(2):494 and <i>Anesth Analg</i>. 2014;118(3):689]. <i>Anesth Analg</i>. 2014;118(1):85-113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/24356162/pubmed" id="24356162" target="_blank">24356162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24395298">
<a name="24395298"></a>García-Gea C, Martínez J, Ballester MR, Gich I, Valiente R, Antonijoan RM. Psychomotor and subjective effects of bilastine, hydroxyzine, and cetirizine, in combination with alcohol: a randomized, double-blind, crossover, and positive-controlled and placebo-controlled Phase I clinical trials. <i>Hum Psychopharmacol</i>. 2014;29(2):120-132. doi:10.1002/hup.2378<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/24395298/pubmed" id="24395298" target="_blank">24395298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goddard.2020">
<a name="Goddard.2020"></a>Goddard J, Stewart PH. Insect and other arthropod bites. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 9, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21154375">
<a name="21154375"></a>Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. <i>Cochrane Database Syst Rev</i>. 2010;(12):CD006815. doi:10.1002/14651858.CD006815.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/21154375/pubmed" id="21154375" target="_blank">21154375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32657014">
<a name="32657014"></a>Hansen C, Desrosiers TA, Wisniewski K, Strickland MJ, Werler MM, Gilboa SM. Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997-2011. <i>Birth Defects Res</i>. 2020;112(16):1234-1252. doi:10.1002/bdr2.1749<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/32657014/pubmed" id="32657014" target="_blank">32657014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Heinonen.1">
<a name="Heinonen.1"></a>Heinonen OP, Slone D, Shapiro S. <i>Birth defects and drugs in pregnancy</i>. Publishing Sciences Group Inc, 1977.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HydroxyzineCaps.2018.07">
<a name="HydroxyzineCaps.2018.07"></a>Hydroxyzine capsules [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; July 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hydroxyzine.2016.08">
<a name="Hydroxyzine.2016.08"></a>Hydroxyzine injection [prescribing information]. Shirley, NY: American Regent Inc; August 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hydroxyzine.2016.08">
<a name="Hydroxyzine.2016.08"></a>Hydroxyzine injection [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HydroxyzineTabs.2016.10">
<a name="HydroxyzineTabs.2016.10"></a>Hydroxyzine tablets [prescribing information]. Congers, NY: Chartwell RX; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HydroxyzineSyrup.2016.01">
<a name="HydroxyzineSyrup.2016.01"></a>Hydroxyzine syrup, oral solution, USP [prescribing information]. Congers, NJ: Chartwell Rx LLC; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31654357">
<a name="31654357"></a>Indraratna P, Tardo D, Delves M, Szirt R, Ng B. Measurement and management of QT interval prolongation for general physicians. <i>J Gen Intern Med</i>. 2020;35(3):865-873. doi:10.1007/s11606-019-05477-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/31654357/pubmed" id="31654357" target="_blank">31654357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8498418">
<a name="8498418"></a>Ito S, Blajchman A, Stephenson M, et al. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. <i>Am J Obstet Gynecol.</i> 1993;168(5):1393-1399. doi:10.1016/s0002-9378(11)90771-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/8498418/pubmed" id="8498418" target="_blank">8498418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25081580">
<a name="25081580"></a>Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i>. 2014;14(suppl 1):s1. doi:10.1186/1471-244X-14-S1-S1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/25081580/pubmed" id="25081580" target="_blank">25081580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khan.2020">
<a name="Khan.2020"></a>Khan DA. Chronic spontaneous urticaria: standard management and patient education. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31782151">
<a name="31782151"></a>Khan M, Wakelin S. Cetirizine induced acute generalized exanthematous pustulosis confirmed by patch testing. <i>Contact Dermatitis</i>. 2020;82(4):238-239. doi:10.1111/cod.13443<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/31782151/pubmed" id="31782151" target="_blank">31782151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35873599">
<a name="35873599"></a>Kocatürk E, Podder I, Zenclussen AC, et al. Urticaria in pregnancy and lactation. <i>Front Allergy</i>. 2022;3:892673. doi:10.3389/falgy.2022.892673<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/35873599/pubmed" id="35873599" target="_blank">35873599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21965865">
<a name="21965865"></a>Kumar SL, Rai R. Hydroxyzine-induced acute generalized exanthematous pustulosis: an uncommon side effect of a common drug. <i>Indian J Dermatol</i>. 2011;56(4):447-448. doi:10.4103/0019-5154.84732<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/21965865/pubmed" id="21965865" target="_blank">21965865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12444816">
<a name="12444816"></a>Llorca PM, Spadone C, Sol O, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. <i>J Clin Psychiatry</i>. 2002;63(11):1020-1027. doi:10.4088/jcp.v63n1112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/12444816/pubmed" id="12444816" target="_blank">12444816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5342863">
<a name="5342863"></a>Malkasian GD Jr, Smith RA, Decker DG. Comparison of hydroxyzine-meperidine and promethazine-meperidine for analgesia during labor. <i>Obstet Gynecol</i>. 1967;30(4):568-575.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/5342863/pubmed" id="5342863" target="_blank">5342863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Martinez.2018">
<a name="Martinez.2018"></a>Martínez LG, González GEC. Cardiotoxicity of H1-antihistamines. <i>J Anal Pharm Res.</i> 2018;7(2):197-201. NLM ID: 101705694 [Serial]</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2892446">
<a name="2892446"></a>Matzke GR, Yeh J, Awni WM, Halstenson CE, Chung M. Pharmacokinetics of cetirizine in the elderly and patients with renal insufficiency. <i>Ann Allergy</i>. 1987;59(6 pt 2):25-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/2892446/pubmed" id="2892446" target="_blank">2892446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3928731">
<a name="3928731"></a>Messinis IE, Souvatzoglou A, Fais N, Lolis D. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. <i>J Endocrinol Invest</i>. 1985;8(2):143-146.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/3928731/pubmed" id="3928731" target="_blank">3928731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nelson.1996">
<a name="Nelson.1996"></a>Nelson WE, Behrman RE, Arvin AM, Kliegman RM, eds. Nelson Textbook of Pediatrics. 15th ed. Philadelphia, PA: WB Saunders Company; 1996: 2058-2078.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11528239">
<a name="11528239"></a>Noiri E, Ozawa H, Fujita T, Nakao A. Pharmacokinetics of cetirizine in chronic hemodialysis patients: multiple-dose study. <i>Nephron</i>. 2001;89(1):101-104. doi:10.1159/000046050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/11528239/pubmed" id="11528239" target="_blank">11528239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30355430">
<a name="30355430"></a>Olacke B, Nelson T, Sarvas E, Scott JM. A retrospective study of dosing weight and outcomes for one pediatric dental sedation regimen. <i>Pediatr Dent</i>. 2018;40(5):346-351.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/30355430/pubmed" id="30355430" target="_blank">30355430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25219740">
<a name="25219740"></a>O'Toole A, Lacroix J, Pratt M, Beecker J. Acute generalized exanthematous pustulosis associated with 2 common medications: hydroxyzine and benzocaine. <i>J Am Acad Dermatol</i>. 2014;71(4):e147-e149. doi:10.1016/j.jaad.2014.05.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/25219740/pubmed" id="25219740" target="_blank">25219740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25711134">
<a name="25711134"></a>Powell RJ, Leech SC, Till S, et al; British Society for Allergy and Clinical Immunology. BSACI guideline for the management of chronic urticaria and angioedema. <i>Clin Exp Allergy</i>. 2015;45(3):547-565.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/25711134/pubmed" id="25711134" target="_blank">25711134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-855838">
<a name="855838"></a>Prenner BM. Neonatal withdrawal syndrome associated with hydroxyzine hydrochloride. <i>Am J Dis Child</i>. 1977;131(5):529-530. doi:10.1001/archpedi.1977.02120180043007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/855838/pubmed" id="855838" target="_blank">855838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Canada.1">
<a name="Canada.1"></a>Refer to Canadian labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20047024">
<a name="20047024"></a>Roach CL, Husain N, Zabinsky J, Welch E, Garg R. Moderate sedation for echocardiography of preschoolers. <i>Pediatr Cardiol</i>. 2010;31(4):469-473.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/20047024/pubmed" id="20047024" target="_blank">20047024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14999113">
<a name="14999113"></a>Roden DM. Drug-induced prolongation of the QT interval. <i>N Engl J Med</i>. 2004;350(10):1013-1022. doi:10.1056/NEJMra032426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/14999113/pubmed" id="14999113" target="_blank">14999113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roy-Byrne.2020">
<a name="Roy-Byrne.2020"></a>Roy-Byrne PP. Management of psychiatric disorders in patients with cancer. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 2, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19057127">
<a name="19057127"></a>Sakaguchi T, Itoh H, Ding WG, et al. Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation. <i>J Pharmacol Sci</i>. 2008;108(4):462-471. doi:10.1254/jphs.08178fp<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/19057127/pubmed" id="19057127" target="_blank">19057127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28480041">
<a name="28480041"></a>Schlit AF, Delaunois A, Colomar A, et al. Risk of QT prolongation and torsade de pointes associated with exposure to hydroxyzine: re-evaluation of an established drug. <i>Pharmacol Res Perspect</i>. 2017;5(3):e00309. doi:10.1002/prp2.309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/28480041/pubmed" id="28480041" target="_blank">28480041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27999468">
<a name="27999468"></a>Sawantdesai NS, Kale PP, Savai J. Evaluation of anxiolytic effects of aripiprazole and hydroxyzine as a combination in mice. <i>J Basic Clin Pharm</i>. 2016;7(4):97-104. doi:10.4103/0976-0105.189429<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/27999468/pubmed" id="27999468" target="_blank">27999468</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16199350">
<a name="16199350"></a>Serreau R, Komiha M, Blanc F, Guillot F, Jacqz-Aigrain E. Neonatal seizures associated with maternal hydroxyzine hydrochloride in late pregnancy. <i>Reprod Toxicol</i>. 2005;20(4):573-574. doi:10.1016/j.reprotox.2005.03.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/16199350/pubmed" id="16199350" target="_blank">16199350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7909915">
<a name="7909915"></a>Simons FE, Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. <i>N Engl J Med</i>. 1994;330(23):1663-1670. doi:10.1056/NEJM199406093302307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/7909915/pubmed" id="7909915" target="_blank">7909915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6361228">
<a name="6361228"></a>Simons FE, Simons KJ, Becker AB, Haydey RP. Pharmacokinetics and antipruritic effects of hydroxyzine in children with atopic dermatitis. <i>J Pediatr</i>. 1984b;104(1):123-127. doi:10.1016/s0022-3476(84)80608-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/6361228/pubmed" id="6361228" target="_blank">6361228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6141198">
<a name="6141198"></a>Simons FE, Simons KJ, Frith EM. The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine. <i>J Allergy Clin Immunol</i>. 1984a;73(1 Pt 1):69-75. doi:10.1016/0091-6749(84)90486-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/6141198/pubmed" id="6141198" target="_blank">6141198</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2572611">
<a name="2572611"></a>Simons FE, Watson WT, Chen XY, Minuk GY, Simons KJ. The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. <i>J Clin Pharmacol</i>. 1989a;29(9):809-815. doi:10.1002/j.1552-4604.1989.tb03424.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/2572611/pubmed" id="2572611" target="_blank">2572611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2562944">
<a name="2562944"></a>Simons KJ, Watson WT, Chen XY, Simons FE. Pharmacokinetic and pharmacodynamic studies of the H1-receptor antagonist hydroxyzine in the elderly. <i>Clin Pharmacol Ther</i>. 1989b;45(1):9-14. doi:10.1038/clpt.1989.2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/2562944/pubmed" id="2562944" target="_blank">2562944</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28793999">
<a name="28793999"></a>Snitker S, Doerfler RM, Soliman EZ, et al; for CRIC Study Investigators. Association of QT-prolonging medication use in CKD with electrocardiographic manifestations. <i>Clin J Am Soc Nephrol</i>. 2017;12(9):1409-1417. doi:10.2215/CJN.12991216<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/28793999/pubmed" id="28793999" target="_blank">28793999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25183382">
<a name="25183382"></a>Soussan C, Gouraud A, Portolan G, et al. Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database. <i>Eur J Clin Pharmacol</i>. 2014;70(11):1361-1366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/25183382/pubmed" id="25183382" target="_blank">25183382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24472058">
<a name="24472058"></a>Staevska M, Gugutkova M, Lazarova C, et al. Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial. <i>Br J Dermatol</i>. 2014;171(1):148-154. doi:10.1111/bjd.12846<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/24472058/pubmed" id="24472058" target="_blank">24472058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26354880">
<a name="26354880"></a>Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. <i>J Am Acad Dermatol</i>. 2015;73(5):843-848. doi:10.1016/j.jaad.2015.07.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/26354880/pubmed" id="26354880" target="_blank">26354880</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30949959">
<a name="30949959"></a>Thomas J, Saple DG, Jerajani HR, et al. Real-world, non-interventional, observational study of hydroxyzine hydrochloride in chronic pruritus: A prospective, non-comparative study. <i>Dermatol Ther (Heidelb)</i>. 2019;9(2):299-308. doi:10.1007/s13555-019-0293-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/30949959/pubmed" id="30949959" target="_blank">30949959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-induced arrhythmias: A scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23716032">
<a name="23716032"></a>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. <i>Circ Cardiovasc Qual Outcomes</i>. 2013;6(4):479-487. doi:10.1161/CIRCOUTCOMES.113.000152 Erratum in: <i>Circ Cardiovasc Qual Outcomes</i>. 2013 Nov;6(6):e57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/23716032/pubmed" id="23716032" target="_blank">23716032</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17927792">
<a name="17927792"></a>Tsai YS, Tu ME, Wu YH, Lin YC. Hydroxyzine-induced acute generalized exanthematous pustulosis. <i>Br J Dermatol</i>. 2007;157(6):1296-1297. doi:10.1111/j.1365-2133.2007.08225.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/17927792/pubmed" id="17927792" target="_blank">17927792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25622983">
<a name="25622983"></a>Vigne J, Alexandre J, Fobe F, et al. QT prolongation induced by hydroxyzine: a pharmacovigilance case report. <i>Eur J Clin Pharmacol</i>. 2015;71(3):379-381. doi:10.1007/s00228-014-1804-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/25622983/pubmed" id="25622983" target="_blank">25622983</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vistaril.2019.09">
<a name="Vistaril.2019.09"></a>Vistaril (hydroxyzine) [prescribing information]. New York, NY: Pfizer; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32439401">
<a name="32439401"></a>Walter HJ, Bukstein OG, Abright AR, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2020;59(10):1107-1124. doi:10.1016/j.jaac.2020.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/32439401/pubmed" id="32439401" target="_blank">32439401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zeltzer.1">
<a name="Zeltzer.1"></a>Zeltzer LK, Krane EJ, Levy RL. Pediatric pain management. In: Kliegman RM, St. Geme J, eds. <i>Nelson Textbook of Pediatrics</i>. 21st ed. Elsevier; 2020:chap. 76.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34536239">
<a name="34536239"></a>Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy</i>. 2022;77(3):734-766. doi:10.1111/all.15090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/hydroxyzine-pediatric-drug-information/abstract-text/34536239/pubmed" id="34536239" target="_blank">34536239</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13368 Version 673.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
